IRIS Accounts Production v24.3.0.553 07767700 Board of Directors Board of Directors Board of Directors 1.10.23 30.9.24 30.9.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh077677002023-09-30077677002024-09-30077677002023-10-012024-09-30077677002022-09-30077677002022-10-012023-09-30077677002023-09-3007767700ns15:EnglandWales2023-10-012024-09-3007767700ns14:PoundSterling2023-10-012024-09-3007767700ns10:Director12023-10-012024-09-3007767700ns10:Director22023-10-012024-09-3007767700ns10:Director32023-10-012024-09-3007767700ns10:PrivateLimitedCompanyLtd2023-10-012024-09-3007767700ns10:SmallEntities2023-10-012024-09-3007767700ns10:AuditExemptWithAccountantsReport2023-10-012024-09-3007767700ns10:SmallCompaniesRegimeForDirectorsReport2023-10-012024-09-3007767700ns10:SmallCompaniesRegimeForAccounts2023-10-012024-09-3007767700ns10:FullAccounts2023-10-012024-09-3007767700ns10:OrdinaryShareClass12023-10-012024-09-3007767700ns10:RegisteredOffice2023-10-012024-09-3007767700ns5:CurrentFinancialInstruments2024-09-3007767700ns5:CurrentFinancialInstruments2023-09-3007767700ns5:ShareCapital2024-09-3007767700ns5:ShareCapital2023-09-3007767700ns5:FurtherSpecificReserve3ComponentTotalEquity2024-09-3007767700ns5:FurtherSpecificReserve3ComponentTotalEquity2023-09-3007767700ns5:FurnitureFittings2023-10-012024-09-3007767700ns5:ComputerEquipment2023-10-012024-09-3007767700ns5:FurnitureFittings2023-09-3007767700ns5:ComputerEquipment2023-09-3007767700ns5:FurnitureFittings2024-09-3007767700ns5:ComputerEquipment2024-09-3007767700ns5:FurnitureFittings2023-09-3007767700ns5:ComputerEquipment2023-09-3007767700ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-09-3007767700ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-09-3007767700ns5:AcceleratedTaxDepreciationDeferredTax2024-09-3007767700ns5:AcceleratedTaxDepreciationDeferredTax2023-09-3007767700ns5:DeferredTaxation2023-09-3007767700ns5:DeferredTaxation2023-10-012024-09-3007767700ns5:DeferredTaxation2024-09-3007767700ns10:OrdinaryShareClass12024-09-3007767700ns5:FurtherSpecificReserve3ComponentTotalEquity2023-09-30
REGISTERED NUMBER: 07767700 (England and Wales)














UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 SEPTEMBER 2024

FOR

SANDEXIS MEDICINAL CHEMISTRY LTD

SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Report of the Accountants 8

SANDEXIS MEDICINAL CHEMISTRY LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 30 SEPTEMBER 2024







DIRECTORS: Dr K R Gibson
Dr J E J Mills
Dr G A Whitlock





REGISTERED OFFICE: 45 Queen Street
Deal
Kent
CT14 6EY





REGISTERED NUMBER: 07767700 (England and Wales)





ACCOUNTANTS: Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY

SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700)

BALANCE SHEET
30 SEPTEMBER 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,596 1,133

CURRENT ASSETS
Debtors 5 376,152 306,693
Investments 6 813,064 590,771
Cash at bank 349,028 352,031
1,538,244 1,249,495
CREDITORS
Amounts falling due within one year 7 273,278 261,030
NET CURRENT ASSETS 1,264,966 988,465
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,266,562

989,598

PROVISIONS FOR LIABILITIES 8 25,821 2,612
NET ASSETS 1,240,741 986,986

CAPITAL AND RESERVES
Called up share capital 9 9,999 9,999
Fair value reserve 10 66,579 (2,641 )
Retained earnings 1,164,163 979,628
SHAREHOLDERS' FUNDS 1,240,741 986,986

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700)

BALANCE SHEET - continued
30 SEPTEMBER 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 10 March 2025 and were signed on its behalf by:




Dr K R Gibson - Director Dr J E J Mills - Director




Dr G A Whitlock - Director


SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

1. STATUTORY INFORMATION

Sandexis Medicinal Chemistry Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The Financial Statements are presented in round pounds sterling £.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover represents net invoiced sales of services, excluding value added tax.
Revenue is recognised when the service is 100% complete.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 25% on cost
Computer equipment - 33% on cost

Tangible fixed assets are tested for impairment annually.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 4 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and Computer
fittings equipment Totals
£    £    £   
COST
At 1 October 2023 2,347 8,826 11,173
Additions - 1,321 1,321
Disposals - (3,799 ) (3,799 )
At 30 September 2024 2,347 6,348 8,695
DEPRECIATION
At 1 October 2023 1,928 8,112 10,040
Charge for year 112 746 858
Eliminated on disposal - (3,799 ) (3,799 )
At 30 September 2024 2,040 5,059 7,099
NET BOOK VALUE
At 30 September 2024 307 1,289 1,596
At 30 September 2023 419 714 1,133

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 107,655 143,620
Other debtors 41,101 42,120
Directors' current accounts 112,976 116,482
Accrued income 109,381 -
Prepayments 5,039 4,471
376,152 306,693

6. CURRENT ASSET INVESTMENTS
2024 2023
£    £   
Unlisted investments 813,064 590,771

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors - 3,768
Tax 231,925 222,148
Social security and other taxes 1,200 754
VAT 38,604 32,765
Other creditors 84 150
Accrued expenses 1,465 1,445
273,278 261,030

SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2024

8. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax
Accelerated capital allowances 309 174
Other timing differences 25,512 2,438
25,821 2,612

Deferred
tax
£   
Balance at 1 October 2023 2,612
Provided during year 23,209
Balance at 30 September 2024 25,821

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
9,999 Ordinary £1 9,999 9,999

10. RESERVES
Fair
value
reserve
£   
At 1 October 2023 (2,641 )
Profit and loss account invest 69,220

At 30 September 2024 66,579

SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 SEPTEMBER 2024

11. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

During the year the following Directors Current Accounts subsisted;

1- a member of key management personnel

During the year the Director repaid the Company £2,475 - (2023 - £333)
During the year the Company advanced the Director £1,875 - (2023 - £65,000)
As at the year end the Director owed the Company £83,962 - (2023: £84,562)
Interest has been charged on the loan balance at 2.25%.

2- a member of key management personnel

During the year the Director repaid the Company £1,734 - (2023 - £1,066)
During the year the Company advanced the Director £325 - (2023 - £NIL)
As at the year end the Director owed the Company £13,892 - (2023 - £15,301)
Interest has been charged on the loan balance at 2.25%.

3- a member of key management personnel

During the year the Director repaid the Company £1,851 - (2023 - £1,263)
During the year the Company advanced the Director £353 - (2023 - £NIL)
As at the year end the Director owed the Company £15,121 - (2023: £16,619)
Interest has been charged on the loan balance at 2.25%.

SANDEXIS MEDICINAL CHEMISTRY LTD

REPORT OF THE ACCOUNTANTS TO THE DIRECTORS OF
SANDEXIS MEDICINAL CHEMISTRY LTD

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 30 September 2024 set out on pages one to twelve and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.






Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY


Date: .............................................